BACKGROUND: The revised classification criteria for the antiphospholipid syndrome (APS) state that antiphospholipid (aPL) antibodies [Lupus Anticoagulant (LAC) and/or anticardiolipin (aCL) and/or anti β2-glycoprotein I (aβ2GPI) antibodies] should be detected on two or more occasions at least 12 weeks apart. Consequently, classification of patients risk and adequacy of treatment may be deferred by three months. OBJECTIVES: In order to early classify patients risk, we evaluated whether aPL positivity confirmation is related to aPL antibody profiles. PATIENTS AND METHODS: Consecutive patients referred to our Center initially positive to one or more tests exploring the presence of aPL were tested after 3 months. During a four-years period 225 patients were initially positive to one or more test and 161 were available for confirmation after 3 months. Patients were classified as triple positive (n=54: LAC+, aCL+, aβ2GPI+, same isotype), double positive (n=50: LAC-, aCL+, aβ2GPI+, same isotype) and single positive (n=53: LAC or aCL or aβ2GPI antibodies as the sole positive test). RESULTS: Among subjects with triple positivity at initial testing, 98% (53out of 54) had their aPL profile confirmed after 12 weeks. Double and single positivity groups had data confirmed in 42 of 50 (84%) and 23 of 57 (40%) subjects, respectively. CONCLUSIONS: Our results show that high risk subjects with triple positive aPL profiles are identified early at time of the initial screening tests.

Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile

PENGO, VITTORIO;RUFFATTI, AMELIA;TONELLO, MARTA;HOXHA, ARIELA;BANZATO, ALESSANDRA;BISON, ELISA;
2013

Abstract

BACKGROUND: The revised classification criteria for the antiphospholipid syndrome (APS) state that antiphospholipid (aPL) antibodies [Lupus Anticoagulant (LAC) and/or anticardiolipin (aCL) and/or anti β2-glycoprotein I (aβ2GPI) antibodies] should be detected on two or more occasions at least 12 weeks apart. Consequently, classification of patients risk and adequacy of treatment may be deferred by three months. OBJECTIVES: In order to early classify patients risk, we evaluated whether aPL positivity confirmation is related to aPL antibody profiles. PATIENTS AND METHODS: Consecutive patients referred to our Center initially positive to one or more tests exploring the presence of aPL were tested after 3 months. During a four-years period 225 patients were initially positive to one or more test and 161 were available for confirmation after 3 months. Patients were classified as triple positive (n=54: LAC+, aCL+, aβ2GPI+, same isotype), double positive (n=50: LAC-, aCL+, aβ2GPI+, same isotype) and single positive (n=53: LAC or aCL or aβ2GPI antibodies as the sole positive test). RESULTS: Among subjects with triple positivity at initial testing, 98% (53out of 54) had their aPL profile confirmed after 12 weeks. Double and single positivity groups had data confirmed in 42 of 50 (84%) and 23 of 57 (40%) subjects, respectively. CONCLUSIONS: Our results show that high risk subjects with triple positive aPL profiles are identified early at time of the initial screening tests.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/2601644
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 70
social impact